Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Pharmacol Ther. 2016 Apr 25;163:48–57. doi: 10.1016/j.pharmthera.2016.03.016

Figure 3. Biomarker Development Pipeline.

Figure 3

The overview is based on estimations and the experiences gained during the Critical Path’s Predictive Safety Testing Consortium’s work on protein biomarkers for kidney injury. *Dependent on platforms used as well as type of biospecimen.